PKCη as a therapeutic target in glioblastoma multiforme

Bibliography

• HOLLAND EC: Gliomagenesis: genetic alterations and mouse models. Nat. Rev Genet. (2001) 2(2):120–129.
   PubMedGoogle Scholar
• •A concise review that describes the genetic changes associated with primary brain tumours.
   Google Scholar
• MISCHEL PS, NELSON SF, CLOUGHESY TF: Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther. (2003) 2(3):242–247.
   PubMed Web of Science ®Google Scholar
• MAHER EA, FURNARI FB, BACHOO RM et al: Malignant glioma: genetics and biology of a grave matter. Genes Dev. (2001) 15(11):1311–1333.
   PubMed Web of Science ®Google Scholar
• MISCHEL PS, CLOUGHESY TF: Targeted molecular therapy of GBM. Brain Pathol (2003) 13(1):52–61.
   PubMed Web of Science ®Google Scholar
• COULD WELL WT, UHM JH, ANTEL JP, YONG VW: Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery (1991) 29(6):880–887.
   PubMedGoogle Scholar
• BENZIL DL, FINKELSTEIN SD, EPSTEIN MH, FINCH PW: Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression. Cancer Res. (1992) 52(10):2951–2956.
   PubMedGoogle Scholar
• COULD WELL WT, ANTEL JP, YONG VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery (1992) 31(4):717–724; discussion 724.
   Google Scholar
• BESSON A, YONG VW: Mitogenic Signaling and the relationship to cell cycle regulation in astrocytomas. Neuro-Oncology (2001) 51(4):245–264.
   Google Scholar
• BREDEL M, POLLACK IF: The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. Acta Neurochir. (Wien) (1997) 139(11):1000–1013.
   PubMedGoogle Scholar
• HUSSAINI IM, KARNS LR, VINTON G et al: Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific proliferative response in astrocytic tumor cells. J. Biol. Chem. (2000) 275(29):22348–22354.
   PubMedGoogle Scholar
• ••This work demonstrates the growthadvantage conferred by PKCti expression in human glioblastoma cell lines.
   Google Scholar
• HUSSAINI IM, CARPENTER JE, REDPATH GT et al: Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. Neuro-oncol (2002) 4(1):9–21.
   PubMedGoogle Scholar
• ••This work describes the role of PKCII inpreventing apoptosis after radiation in human glioblastoma cell lines.
   Google Scholar
• NISHIZUKA Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (1988) 334(6184):661–665.
   PubMed Web of Science ®Google Scholar
• •This paper represents a seminal paper in the study of PKCs.
   Google Scholar
• PARKER PJ, MURRAY-RUST J: PKC at a glance. Cell Sci. (2004) 117(Pt 2):131–132.
   PubMedGoogle Scholar
• ••This recent review highlights theregulation of PKC activation and PKC interacting proteins.
   Google Scholar
• HURLEY JH, NEWTON AC, PARKER PJ, BLUMBERG PM, NISHIZUKA Y: Taxonomy and function of Cl protein kinase C homology domains. Protein Sci. (1997) 6(2):477–480.
   PubMedGoogle Scholar
• KAZANIETZ MG, BUSTELO XR, BARBACID M: Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. J. Biol Chem. (1994) 269(15):11590–11594.
   Google Scholar
• PEARS CJ, KOUR G, HOUSE C, KEMP BE, PARKER PJ: Mutagenesis of the pseudosubstrate site of protein kinase C leads to activation. Eur. Biochem. (1990) 194(1):89–94.
   PubMedGoogle Scholar
• NISHIZUKA Y: The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature (1984) 308(5961):693–698.
   PubMed Web of Science ®Google Scholar
• GOTO K, KONDO H: Diacylglycerol kinase in the central nervous system-molecular heterogeneity and gene expression. Chem. Phys. Lipids (1999) 98(1-2):109–117.
   PubMedGoogle Scholar
• NEWTON AC: Regulation of protein kinase C. Curr. Opin. Cell Biol. (1997) 9(2):161–167.
   PubMed Web of Science ®Google Scholar
• NEWTON AC: Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev (2001) 101(8):2353–2364.
   PubMed Web of Science ®Google Scholar
• NEWTON AC: Protein kinase C: structure, function, and regulation. J. Biol. Chem. (1995) 270(48):28495–28498.
   PubMedGoogle Scholar
• TREMBLAY F, LAVIGNE C, JACQUES H, MARETTE A: Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/ protein kinase B and atypical protein kinase C (zeta/lambda) activities. Diabetes (2001) 50(8):1901–1910.
   PubMedGoogle Scholar
• CHOU MM, HOU W, JOHNSON J et al: Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr. Biol. (1998) 8(19):1069–1077.
   PubMed Web of Science ®Google Scholar
• AEDER SE, MARTIN PM, SOH JW, HUSSAINI IM: PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene (2004) 23(56):9062–9069.
   PubMed Web of Science ®Google Scholar
• KRONER C, EYBRECHTS K, AKKERMAN JW: Dual regulation of platelet protein kinase B. J. Biol. Chem. (2000) 275(36):27790–27798.
   PubMedGoogle Scholar
• KAWAKAMI Y, NISHIMOTO H, KITAURA J et al.: Protein kinase C beta II regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J. Biol. Chem. (2004)
   Google Scholar
• SCHONWASSER DC, MARAIS RM, MARSHALL CJ, PARKER PJ: Activation of the mitogen-activated protein kinase/ extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell. Biol. (1998) 18(2):790–798.
   PubMedGoogle Scholar
• ••A comprehensive study investigating theregulation of MAPK signaling downstream of PKC activation.
   Google Scholar
• MARAIS R, LIGHT Y, MASON C et al: Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science (1998) 280(5360):109–112.
   PubMed Web of Science ®Google Scholar
• BRANDLIN I, HUBNER S, EISELER T et al: Protein kinase C (PKC)eta-mediated PKC mu activation modulates ERK and JNK signal pathways. I Biol. Chem. (2002) 277(8):6490–6496.
   Google Scholar
• BESSON A, YONG VW: Involvement of p21(Wafl/Cip1) in protein kinase C alpha-induced cell cycle progression. Mol Cell. Biol. (2000) 20(13):4580–4590.
   PubMedGoogle Scholar
• CASTAGNA M, TAKAI Y, KAIBUCHI K et al: Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. (1982) 257(13):7847–7851.
   PubMed Web of Science ®Google Scholar
• DA ROCHA AB, MANS DR, REGNER A, SCHWARTSMANN G: Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist (2002) 7(1):17–33.
   PubMedGoogle Scholar
• •A comprehensive review of PKCs as molecular targets in GBM.
   Google Scholar
• MACKAY HJ, TWELVES CJ: Protein kinase C: a target for anticancer drugs? Endocr. Relat. Cancer (2003) 10(3):389–396.
   PubMedGoogle Scholar
• •A review article discussing the use of PKC inhibitors as treatments for cancer.
   Google Scholar
• DETJEN KM, BREMBECK FH, WELZEL M et al.: Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J. Cell Sci. (2000) 113 (Pt 17):3025–3035.
   PubMed Web of Science ®Google Scholar
• DENHAM DW, FRANZ MG, DENHAM W et al.: Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery (1998) 124(2):218–223; discussion 223–214.
   Google Scholar
• BASU A, WEIXEL K, SAIJO N: Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Cell Growth Differ. (1996) 7(10:1507–1512.
   PubMedGoogle Scholar
• WANG XY, REPASKY E, LIU HT: Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells. Exp. Cell Res. (1999) 250(1):253–263.
   PubMedGoogle Scholar
• MAWRIN C, DIETE S, TREUHEIT T et al.: Prognostic relevance of MAPK expression in glioblastoma multiforme. Int. J. Oncol (2003) 23(3):641–648.
   PubMedGoogle Scholar
• MURRAY NR, DAVIDSON LA, CHAPKIN RS et al: Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J. Cell Biol. (1999) 145(4):699–711.
   PubMedGoogle Scholar
• ZHANG J, ANASTASIADIS PZ, LIU Y, THOMPSON EA, FIELDS AP: Protein kinase C (PKC) betall induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J. Biol. Chem. (2004) 279(21):22118–22123.
   PubMedGoogle Scholar
• PERSONS DA, OWEN RD, OSTROWSKI MC, FINN OJ: Protein kinase C gamma expression mimics phorbol ester-induced transcriptional activation of a murine VL30 enhancer element. Cell Growth Differ. (1991) 2(1):7–14.
   PubMedGoogle Scholar
• PERSONS DA, WILKISON WO, BELL RM, FINN OJ: Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-I cDNA. Cell (1988) 52(3):447–458.
   PubMedGoogle Scholar
• MAZZONI E, ADAM A, BAL DE KIER JOFFE E, AGUIRRE-GHISO JA: Immortalized mammary epithelial cells overexpressing protein kinase C gamma acquire a malignant phenotype and become tumorigenic in vivo. Mol Cancer Res. (2003) 1(10):776–787.
   PubMedGoogle Scholar
• NI H, ERGIN M, TIBUDAN SS et al: Protein kinase C-delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis. BE J. Haematol (2003) 121(6):849–856.
   PubMedGoogle Scholar
• MCCRACKEN MA, MIRAGLIA LJ, MCKAY RA, STROBL JS: Protein kinase C delta is a prosurvival factor in human breast tumor cell lines. Mol. Cancer Ther. (2003) 2(3):273–281.
   PubMedGoogle Scholar
• JANSEN AP, VERWIEBE EG, DRECKSCHMIDT NE et al: Protein kinase C-epsilon transgenic mice: a unique model for metastatic squamous cell carcinoma. Cancer Res. (2001) 61(3):808–812.
   PubMedGoogle Scholar
• KILEY SC, CLARK KJ, DUDDY SK, WELCH DR, JAKEN S: Increased protein kinase C delta in mammary tumor cells: relationship to transformtion and metastatic progression. Oncogene (1999) 18(48):6748–6757.
   PubMedGoogle Scholar
• DING L, WANG H, LANG W, XIAO L: Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway. J. Biol. Chem. (2002) 277(38):35305–35313.
   PubMedGoogle Scholar
• MCJILTON MA, VAN SIKES C, WESCOTT GG et al: Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene (2003) 22(39):7958–7968.
   PubMedGoogle Scholar
• BECK J, HAND GRETINGER R, KLINGEBIEL T et al: Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia (1996) 10(3):426–433.
   PubMedGoogle Scholar
• WAYS DK, POSEKANY K, DEVENTE J et al.: Overexpression of protein kinase C-zeta stimulates leukemic cell differentiation. Cell Growth Differ. (1994) 5(10:1195–1203.
   PubMedGoogle Scholar
• SHIH SC, MULLEN A, ABRAMS K, MUKHOPADHYAY D, CLAFFEY KP: Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells. .1 Biol. Chem. (1999) 274(22):15407–15414.
   Google Scholar
• XIAO H, GOLDTHWAIT DA, MAPSTONE T: The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC alpha, gamma, epsilon, and zeta. J. Neurosurg. (1994) 81(5):734–740.
   PubMedGoogle Scholar
• LAUDANNA C, SORIO C, TECCHIO C et al.: Motility analysis of pancreatic adenocarcinoma cells reveals a role for the atypical zeta isoform of protein kinase C in cancer cell movement. Lab. Invest. (2003) 83(8):1155–1163.
   PubMedGoogle Scholar
• WEICHERT W, GEKELER V, DENKERT C, DIETEL M, HAUPTMANN S: Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int. J. Oncol (2003) 23(3):633–639.
   PubMedGoogle Scholar
• MURRAY NR, FIELDS AP: Atypical protein kinase C iota protects human leukemia cells against drug-induced apoptosis. ./. Biol. Chem. (1997) 272(44):27521–27524.
   PubMedGoogle Scholar
• MURRAY NR, JAMIESON L, YU W et al.: Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J. Cell Biol. (2004) 164(6):797–802.
   PubMedGoogle Scholar
• BRUGGER D, BRISCHWEIN K, LIU C et al.: Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. Anti-Cancer Res. (2002) 22(6C):4229–4232.
   Google Scholar
• BECK J, BOHNET B, BRUGGER D et al: Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression. BE J. Cancer (1998) 77(1):87–91.
   Google Scholar
• LANGZAM L, KOREN R, GAL R et a/.: Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy. Am. J. Clin. Pathol (2001) 116(3):377–385.
   Google Scholar
• BRENNER W, FARBER G, HERGET T et al: Protein kinase C eta is associated with progression of renal cell carcinoma (RCC). Anti-Cancer Res. (2003) 23(5A):4001–4006.
   Google Scholar
• MASSO-WELCH PA, WINSTON JS, EDGES et al: Altered expression and localization of PKC eta in human breast tumors. Breast Cancer Res. Treat. (2001) 68(3):211–223.
   PubMedGoogle Scholar
• AKKARAJU GR, BASU A: Overexpression of protein kinase C-eta attenuates caspase activation and tumor necrosis factor-alpha-induced cell death. Biochem. Biophys. Res. Commun. (2000) 279(1):103–107.
   PubMedGoogle Scholar
• MATSUMURA M, TANAKA N, KUROKI T, ICHIHASHI M, OHBA M: The eta isoform of protein kinase C inhibits UV-induced activation of caspase-3 in normal human keratinocytes. Biochem. Biophys. Res. Commun. (2003) 303(1):350–356.
   PubMedGoogle Scholar
• •PKCII as an antiapoptotic regulatory protein in human skin cells.
   Google Scholar
• OHBA M, ISHINO K, KASHIWAGI M et al.: Induction of differentiation in normal human keratinocytes by adenovirus-mediated introduction of the eta and delta isoforms of protein kinase C. Mol Cell. Biol. (1998) 18(9):5199–5207.
   PubMedGoogle Scholar
• CHIDA K, HARA T, HIRAI T et al: Disruption of protein kinase Ceta results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis. Cancer Res. (2003) 63(10):2404–2408.
   PubMedGoogle Scholar
• MISRA-PRESS A, FIELDS AP, SAMOLS D, GOLDTHWAIT DA: Protein kinase C isoforms in human glioblastoma cells. Clio (1992) 6(3):188–197.
   Google Scholar
• ••This paper is one of the first reportsdescribing the expression of PKC isozymes in glioblastomas.
   Google Scholar
• BALTUCH GH, DOOLEY NP, ROSTWOROWSKI KM, VILLEMURE JG, YONG VW: Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation. Neurooncol (1995) 24(3):241–250.
   PubMedGoogle Scholar
• MANDIL R, ASHKENAZI E, BLASS M et al.: Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res. (2001) 61(11):4612–4619.
   PubMed Web of Science ®Google Scholar
• SHEN L, GLAZER RI: Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of p53 and induction of the insulin-like growth factor-1-binding protein-3. Biochem. Pharmacol (1998) 55(10):1711–1719.
   PubMed Web of Science ®Google Scholar
• SATO K, ISHIKAWA K, UI M, OKAJIMA F: Sphingosine 1-phosphate induces expression of early growth response-1 and fibroblast growth factor-2 through mechanism involving extracellular signal-regulated kinase in astroglial cells. Brain Res. Mol Brain Res. (1999) 74(1-2):182–189.
   PubMedGoogle Scholar
• AUGUSTE P, GURSEL DB, LEMIERE S et al.: Inhibition of fibroblast growth factor/ fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res. (2001) 61(4):1717–1726.
   PubMedGoogle Scholar
• COSTANZI-STRAUSS E, STRAUSS BE, NAVIAUX RK, HAAS M: Restoration of growth arrest by pl6INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines. Exp. Cell Res. (1998) 238(1):51–62.
   PubMedGoogle Scholar
• KOMINSKY S, JOHNSON HM, BRYAN G et al.: IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP 1. Oncogene (1998) 17(23):2973–2979.
   PubMedGoogle Scholar
• MISHIMA K, OHNO S, SHITARA N, YAMAOKA K, SUZUKI K: Opposite effects of the overexpression of protein kinase C gamma and delta on the growth properties of human glioma cell line U251 MG. Biochem. Biophys. Res. Commun. (1994) 201(1):363–372.
   PubMedGoogle Scholar
• BRODIE C, KUPERSTEIN I, ACS P, BLUMBERG PM: Differential role of specific PKC isoforms in the proliferation of glial cells and the expression of the astrocytic markers GFAP and glutamine synthetase. Brain Res. Mol Brain Res. (1998) 56(1-2):108–117.
   PubMedGoogle Scholar
• HOVELMANN S, BECKERS TL, SCHMIDT M: Molecular alterations in apoptotic pathways after PKB/ Akt-mediated chemoresistance in NCI H460 cells. Br. Cancer (2004) 90(12):2370–2377.
   Google Scholar
• TANG D, OKADA H, RULAND J et al: Akt is activated in response to an apoptotic signal. J. Biol. Chem. (2001) 276(32):30461–30466.
   PubMedGoogle Scholar
• SHINOHARA H, KAYAGAKI N, YAGITA H et al.: A protective role of PKCepsilon against TNF-related apoptosis-inducing ligand (TRAM-induced apoptosis in glioma cells. Biochem. Biophys. Res. Commun. (2001) 284(5):1162–1167.
   PubMedGoogle Scholar
• BLASS M, KRONFELD I, KAZIMIRSKY G, BLUMBERG PM, BRODIE C: Tyrosine phosphorylation of protein kinase Cdelta is essential for its apoptotic effect in response to etoposide. Mol Cell. Biol. (2002) 22(1):182–195.
   PubMedGoogle Scholar
• KRONFELD I, KAZIMIRSKY G, LORENZO PS et al.: Phosphorylation of protein kinase Cdelta on distinct tyrosine residues regulates specific cellular functions. J. Biol. Chem. (2000) 275(45):35491–35498.
   PubMedGoogle Scholar
• VANMETER TE, ROOPRAI HK, KIBBLE MM et al: The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. Neurooncol (2001) 53(2):213–235.
   PubMed Web of Science ®Google Scholar
• PARK MJ, PARK IC, HUR JH et al: Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/ tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells. Neurosci. Lett. (2000) 290(3):201–204.
   PubMedGoogle Scholar
• CHO KK, MIKKELSEN T, LEE YJ et al: The role of protein kinase Calpha in U-87 glioma invasion. Int. I Dev. Neurosci. (1999) 17(5-6):447–461.
   PubMedGoogle Scholar
• •This paper conclusively demonstrates the regulation of glioma invasion by PKCa.
   Google Scholar
• KERMORGANT S, ZICHA D, PARKER PJ: PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO. J. (2004) 23(19):3721–3734.
   PubMedGoogle Scholar
• KUNKEL P, MULLER S, SCHIRMACHER P et al.: Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-oncol. (2001) 3(2):82–88.
   PubMedGoogle Scholar
• CHATTOPADHYAY N, TFELT-HANSEN J, BROWN EM: PKC, p42/44 MAPK and p38 MAPK regulate hepatocyte growth factor secretion from human astrocytoma cells. Broth Res. Mol Brain Res. (2002) 102(1-2):73–82.
   PubMedGoogle Scholar
• IVASKA J, WHELAN RD, WATSON R, PARKER PJ: PKC epsilon controls the traffic of betal integrins in motile cells. Embo. J. (2002) 21(103608–3619.
   Google Scholar
• BESSON A, WILSON TL, YONG VW: The anchoring protein RACK1 links protein kinase Cepsilon to integrin beta chains. Requirements for adhesion and motility. J. Biol. Chem. (2002) 277(24):22073–22084.
   Google Scholar
• BESSON A, DAVY A, ROBBINS SM, YONG VW: Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene (2001) 20(50):7398–7407.
   PubMedGoogle Scholar
• ESTEVE PO, CHICOINE E, ROBLEDO O et al.: Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. J. Biol. Chem. (2002) 277(38):35150–35155.
   PubMedGoogle Scholar
• YOSHIJI H, KURIYAMA S, WAYS DK et al.: Protein kinase C lies on the signaling pathway for vascular endothelial growth 59(17):4413–4418.
   Google Scholar
• PAL S, CLAFFEY KP, DVORAK HF, MUKHOPADHYAY D: The von vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. (1997) 272(44):27509–27512.
   PubMedGoogle Scholar
• TEICHER BA, MENON K, ALVAREZ E et al.: Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin. Cancer Res. (2001) 7(3):634–640.
   PubMedGoogle Scholar
• WANG A, NOMURA M, PATAN S, WARE JA: Inhibition of protein kinase Calpha prevents endothelial cell migration and vascular tube formation in vitro and myocardial neovascularization in vivo. Circ. Res. (2002) 90(5):609–616
   PubMedGoogle Scholar
• HARRINGTON EO, DOYLE KE, BRUNELLE JL, WARE JA: Endothelial proliferation, migration, and differentiation are blunted by conditionally expressed 271(2):499–508.
   Google Scholar
• SHIZUKUDA Y, TANG S, YOKOTA R, WARE JA: Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. Circ. Res. (1999) 85(3):247–256.
   PubMedGoogle Scholar
• HARRINGTON EO, LOFFLER J, NELSON PR et al.: Enhancement of migration by protein kinase Calpha and inhibition of proliferation and cell cycle progression by protein kinase Cdelta in capillary endothelial cells. ./. Biol. Chem. (1997) 272(10:7390–7397.
   PubMedGoogle Scholar
• GOEKJIAN PG, JIROUSEK MR: Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs (2001) 10(12):2117–2140.
   PubMed Web of Science ®Google Scholar
• •A review discussing the potential that PKC isozymes could have as chemotherapeutic targets in cancer.
   Google Scholar
• RAMACHANDRAN C, KHATIB Z, PETKAROU A et al: Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth Factor II expression in brain tumor cells. Neurooncol. (2004) 67 (1-2) :19–28.
   PubMedGoogle Scholar
• BURSZTAJN S, FENG JJ, NANDA A, BERMAN SA: Differential responses of human neuroblastoma and glioblastoma to apoptosis. Brain Res. Mol Brain Res. (2001) 91(1-2):57–72.
   PubMedGoogle Scholar
• ZHANG W, LAW RE, HINTON DR, COULDWELL WT: Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Lett. (1997) 120(1):31–38.
   PubMedGoogle Scholar
• BEGEMANN M, KASHIMAWO SA, HEITJAN DF et al.: Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. Anti-Cancer Res. (1998) 18(442275–2282.
   Google Scholar
• COULD WELL WT, HINTON DR, HE S et al: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett. (1994) 345(1):43–46.
   PubMedGoogle Scholar
• POLLACK IF, DAROSSO RC, ROBERTSON PL et al.: A Phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin. Cancer Res. (1997) 3(7):1109–1115.
   PubMedGoogle Scholar
• COULD WELL WT, HINTON DR, SURNOCK AA et al: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin. Cancer Res. (1996) 2(4):619–622.
   PubMedGoogle Scholar
• PUCHNER MJ, GIESE A: Tamoxifen-resistant glioma-cell sub-populations are characterized by increased migration and proliferation. Int J. Cancer (2000) 86(4):468–473.
   PubMedGoogle Scholar
• CHEN TC, SU S, FRY D, LIEBES L: Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer (2003) 97(9 Suppl.):2363–2373.
   Google Scholar
• HIROSE Y, BERGER MS, PIEPER RO: Abrogation of the Chkl-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. (2001) 61(15):5843–5849.
   PubMed Web of Science ®Google Scholar
• BREDEL M, POLLACK IF, FREUND JM, RUSNAK J, LAZO JS: Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. ./. Neurooncol. (1999) 41(1):9–20.
   PubMedGoogle Scholar
• HIROSE Y, KATAYAMA M, BERGER MS, PIEPER RO: Cooperative function of Chkl and p38 pathways in activating G2 arrest following exposure to temozolomide. ./. Neurosurg. (2004) 100(6):1060–1065.
   PubMedGoogle Scholar
• POLLACK IF, KAWECKI S, LAZO JS: Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J. Neurosurg. (1996) 84(6):1024–1032.
   PubMedGoogle Scholar
• KORTMANSKY J, SCHWARTZ GK: Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. (2003) 21(6):924–936.
   PubMed Web of Science ®Google Scholar
• PFISTER DG, MCCAFFREY J, ZAHALSKY AJ et al: A Phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Invest. New Drugs (2002) 20(1):123–127.
   PubMedGoogle Scholar
• HAAS NB, SMITH M, LEWIS N et al: Weekly bryostatin-1 in metastatic renal cell carcinoma: a Phase II study. Clin. Cancer Res. (2003) 9(1):109–114.
   PubMed Web of Science ®Google Scholar
• BARYZA JL, BRENNER SE, CRASKE ML, MEYER T, WENDER PA: Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP. Chem. Biol. (2004) 11(9):1261–1267.
   PubMedGoogle Scholar
• KOBAYASHI E, ANDO K, NAKANO H et al.: Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physico-chemical properties and biological activities. Antibiot. (Tokyo) (1989) 42(10):1470–1474.
   PubMedGoogle Scholar
• KOBAYASHI E, ANDO K, NAKANO H, TAMAOKI T: UCN-1028A, a novel and specific inhibitor of protein kinase C, from Cladosporium. Antibiot. (Tokyo) (1989) 42(1):153–155.
   PubMedGoogle Scholar
• ACEVEDO-DUNCAN M, PEARLMAN J, ZACHARIAH B: Sensitivity of human glioma U-373MG cells to radiation and the protein kinase C inhibitor, calphostin C. Cell Prolff (2001) 34(1):31–41.
   PubMedGoogle Scholar
• IKEMOTO H, TANI E, OZAKI I, KITAGAWA H, ARITA N: Calphostin C-mediated translocation and integration of Box into mitochondria induces cytochrome c release before mitochondrial dysfunction. Cell Death Differ. (2000) 7(6):511–520.
   PubMedGoogle Scholar
• DA ROCHA AB, MANS DR, LENZ G et al: Protein kinase C-mediated in vitro invasion of human glioma cells through extracellular-signal-regulated kinase and ornithine decarboxylase. Pathobiology (2000) 68(3):113–123.
   PubMedGoogle Scholar
• ENGELHARD HH: Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors. Cancer Control (1998) 5(2):163–170.
   PubMedGoogle Scholar
• YAZAKI T, AHMAD S, CHAHLAVI A et al.: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol (1996) 50(2):236–242.
   PubMedGoogle Scholar
• SHEN L, DEAN NM, GLAZER RI: Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide. Mol Pharmacol (1999) 55(2):396–402.
   PubMedGoogle Scholar
• ADVANI R, PEETHAMBARAM P, LUM BL et al.: A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer (2004) 100(2):321–326.
   PubMed Web of Science ®Google Scholar
• MANI S, RUDIN CM, KUNKEL K et al.: Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin. Cancer Res. (2002) 8(4):1042–1048.
   PubMed Web of Science ®Google Scholar
• •This study reports a finding that suggests PKCa antisense ODNs may be effective if combined with other chemotherapeutics.
   Google Scholar
• SONNEMANN J, GEKELER V, AHLBRECHT K et al: Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel. Cancer Lett. (2004) 209(2):177–185.
   PubMedGoogle Scholar
• SONNEMANN J, GEKELER V, SAGRAUSKE A et al: Down-regulation of protein kinase Ceta potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells. Mol Cancer Ther. (2004) 3(7):773–781.
   PubMedGoogle Scholar
• ELBASHIR SM, HARBORTH J, LENDECKEL W et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494–498.
   PubMed Web of Science ®Google Scholar
• •First article to demonstrate the effectiveness of siRNA in mammalian cells.
   Google Scholar
• YIN JQ, GAO J, SHAO R et al: siRNA agents inhibit oncogene expression and attenuate human tumor cell growth. Exp. Ther. Oncol (2003) 3(4):194–204.
   PubMedGoogle Scholar
• IRIE N, SAKAI N, UEYAMA T et al: Subtype- and species-specific knockdown of PKC using short interfering RNA. Biochem. Biophys. Res. Commun. (2002) 298(5):738–743.
   PubMedGoogle Scholar
• LEIRDAL M, SIOUD M: Gene-array analysis of glioma cells after treatment with an anti-PKCalpha siRNA: a general protocol. Methods Mol Biol. (2004) 252:493–500.
   PubMedGoogle Scholar
• ••This article describes in detail the protocolused to assay gene expression changes following siRNA treatment in human glioblastoma cells.
   Google Scholar
• UCHIDA H, TANAKA T, SASAKI K et al: Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol .Ther. (2004) 10(1):162–171.
   PubMed Web of Science ®Google Scholar
• KONNIKOVA L, KOTECKI M, KRUGER MM, COCHRAN BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer (2003) 3(1):23.
   PubMedGoogle Scholar
• DING Q, STEWART J, JR., OLMAN MA, KLOBE MR, GLADSON CL: The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged../. Biol. Chem. (2003) 278(40:39882–39891.
   Google Scholar